Clinical-stage biopharmaceutical company Accent Therapeutics on Friday presented preclinical data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California.

Accent's presentation included preclinical data demonstrating the strong anti-tumour activity of ATX-295 across multiple solid tumour indications with high levels of chromosomal instability. The molecule showed potent in vitro activity in high-grade serous ovarian cancer (HGSOC), squamous non-small cell lung cancer (sqNSCLC), and triple-negative breast cancer (TNBC) cell lines, leading to cell cycle arrest and apoptosis.

According to the company, ATX-295 showed robust and durable tumour regression in patient-derived xenograft models of HGSOC, sqNSCLC and TNBC exhibiting whole-genome doubling (WGD), supporting WGD and chromosomal instability as predictive markers of tumour sensitivity to ATX-295. The results also include proof of concept for a novel, artificial intelligence (AI)-based method capable of rapidly detecting WGD in clinical samples, providing the foundation for a clinically feasible biomarker.

ATX-295 is currently under investigation in a first-in-human, Phase 1/2, open-label, dose escalation and expansion study, designed to evaluate the molecule's safety, tolerability, and preliminary efficacy in patients with locally advanced or metastatic solid tumours, including HGSOC and sqNSCLC.